Roche selects Cyprotex for drug discovery support
The Cyprotex group has entered into an agreement with Roche to provide drug discovery support.
Under the terms of the agreement, Cyprotex will provide experimental services that will enable Roche scientists to evaluate and optimise the ADME properties of potential drug candidates early in the drug discovery process.
Commenting on the agreement with Roche, Mark Egerton, ceo of Cyprotex, said: 'We are extremely pleased to be working with Roche, a leading global pharmaceutical company. The fact that Roche selected Cyprotex after a rigorous due diligence process represents another validation step in the development of our business.'
Philippe Coassolo, head of discovery-DMPK at Roche Basel, said: 'We have selected Cyprotex to support our drug discovery projects as they clearly demonstrated that their science and technology platform in ADME testing has the potential to offer a close ongoing relationship between our two companies.'